ALX Oncology raises $105 million in Series C financing for CD47 trials
By Akshay Kedari  Date: 2020-02-14

ALX Oncology raises $105 million in Series C financing for CD47 trials

ALX Oncology, a clinical-stage biotechnology company, has secured $105 million in a Series C funding round, led by Vivo Capital. The new investors, who participated in the funding round include Janus Henderson, Logos Capital, Foresite Capital, BVF Partners, HBM Healthcare Investments, and Cormorant Asset Management. The Series C funding round also witnessed the participation of existing investors Lightstone Ventures and Existing investors venBio, who had participated in the previous two rounds.

The latest funds will be used to further phase 2 study of CD47 myeloid checkpoint inhibitor ALX148 along with other anti-cancer treatments. The Series C funding round comes after the revelation of data by ALX on patients suffering from relapsed or refractory non-Hodgkin lymphoma (NHL), who have been treated using ALX148 in combination with rituximab. Among the 21 evaluable subjects, the company observed a median progression-free survival of 7.3 months and an objective response rate of around 43%. The drug was noted to be well tolerated and relatively safe.

Corey Goodman, Co-Founder and Executive Chairman, ALX, reportedly stated that from the initial days, the company believed that it will be the best-in-class in the CD47 checkpoint pathway by utilizing a ‘dead’ Fc domain that does not bind to macrophages, thus lessening the cytopenias and other toxicities related to this class of agents. The company is elated to observe the clinical results supporting its hypothesis and offering the opportunity for higher dosing and increased efficacy, he further added.

The phase 1 study, that generated the lymphoma data is progressing with other arms of the trial testing the potential of CD47 in combination with Keytruda and Herceptin in patients suffering from a solid tumor. But, with ALX148 coming through its first trial in NHL, ALX intends to take the candidate deeper into the clinic. The series C financing proceeds will be used to bankroll the further development of ALX148. 
 

Source links:

https://www.fiercebiotech.com/biotech/alx-raises-105m-for-midphase-trials-cd47-cancer-drug

 

About Author

Akshay Kedari    

Akshay Kedari

A qualified computer engineering graduate, Akshay Kedari takes pride in having his way with words. Following his passion for content creation, he writes insightful pieces on aeresearch.net and a few other portals. Also endorsed with a short-term experience in web deve...

Read More

More News By Akshay Kedari

Open security group launch a new language to connect security tools
Open security group launch a new language to connect security tools
By Akshay Kedari

The Open Cybersecurity Alliance (OCA), a group of suppliers dedicated to connecting fragmented cybersecurity space with open source practices and codes, has reportedly announced the availability of Open DXL (Data Exchange Layer) Ontology, a new open-...

TÜV Rheinland launches automatic parking system services
TÜV Rheinland launches automatic parking system services
By Akshay Kedari

TÜV Rheinland Hong Kong, a global leader in independent inspection services, has reportedly rolled out an automatic parking system service, covering all facets of the construction, design as well as operation stages. It offers one-stop solutions...

Embracer Group purchases Saber Interactive in a $525 million deal
Embracer Group purchases Saber Interactive in a $525 million deal
By Akshay Kedari

Embracer Group, a renowned video game holding company and owner of THQ Nordic, has reportedly purchased Saber Interactive, a US games developer, in a deal worth $525 million. Embracer Group had agreed to pay $150 million in both cash as well as stoc...

CDK announces launch of new Repair Order API on Fortellis platform
CDK announces launch of new Repair Order API on Fortellis platform
By Akshay Kedari

CDK Global Inc. has recently announced the launch of the CDK Drive Repair Order API (application programming interface) on Fortellis Automotive Commerce Exchange™ platform. In order to enable dealers to securely open and edit service repair or...

US expands lawsuit against Huawei with charges of theft & racketeering
US expands lawsuit against Huawei with charges of theft & racketeering
By Akshay Kedari

The United States Department of Justice has recently expanded its lawsuit against Huawei, a Chinese multinational tech company. The new charges against the company alleged activities carried out by Huawei such as violating partnership terms with U.S....